Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KDR Q472H |
| Therapy | Everolimus + Vandetanib |
| Indication/Tumor Type | epithelioid sarcoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KDR Q472H | epithelioid sarcoma | predicted - sensitive | Everolimus + Vandetanib | Case Reports/Case Series | Actionable | In a Phase I trial, treatment with the combination of Afinitor (everolimus) and Caprelsa (vandetanib) was well tolerated and resulted in a median progression-free survival of 3.3 months, median overall survival of 4.6 months, clinical benefit rate of 38% in pediatric and young adult patients with advanced solid tumors, including 1 partial response in a 20 year-old patient with metastatic epithelioid sarcoma harboring germline KDR Q472H (PMID: 37879233; NCT01582191). | 37879233 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37879233) | Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. | Full reference... |